Content area
Title
Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping
Author
Baca, Sylvan C. 1 ; Seo, Ji-Heui 2 ; Davidsohn, Matthew P. 2 ; Fortunato, Brad 1 ; Semaan, Karl 3 ; Sotudian, Shahabbedin 1
; Lakshminarayanan, Gitanjali 2 ; Diossy, Miklos 4 ; Qiu, Xintao 2
; El Zarif, Talal 2 ; Savignano, Hunter 2 ; Canniff, John 2 ; Madueke, Ikenna 2 ; Saliby, Renee Maria 2
; Zhang, Ziwei 1 ; Li, Rong 2
; Jiang, Yijia 2 ; Taing, Len 2 ; Awad, Mark 5 ; Chau, Cindy H. 6
; DeCaprio, James A. 7
; Figg, William D. 6
; Greten, Tim F. 8
; Hata, Aaron N. 9
; Hodi, F. Stephen 10 ; Hughes, Melissa E. 10 ; Ligon, Keith L. 11
; Lin, Nancy 10 ; Ng, Kimmie 10
; Oser, Matthew G. 10
; Meador, Catherine 9 ; Parsons, Heather A. 10
; Pomerantz, Mark M. 2 ; Rajan, Arun 12
; Ritz, Jerome 10
; Thakuria, Manisha 13 ; Tolaney, Sara M. 10
; Wen, Patrick Y. 14 ; Long, Henry 2
; Berchuck, Jacob E. 2
; Szallasi, Zoltan 15
; Choueiri, Toni K. 10
; Freedman, Matthew L. 1
1 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Eli and Edythe L. Broad Institute, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)
2 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
3 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Eli and Edythe L. Broad Institute, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)
4 Boston Children’s Hospital, Computational Health Informatics Program, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438)
5 Dana-Farber Cancer Institute, Harvard Medical School, Lowe Center for Thoracic Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
6 National Cancer Institute, National Institutes of Health, Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
7 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Brigham and Women’s Hospital, Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
8 National Cancer Institute, National Institutes of Health, Liver Cancer Program, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
9 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital and Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
10 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
11 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Department of Pathology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
12 National Cancer Institute, National Institute of Health, Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
13 Brigham and Women’s Hospital, Harvard Medical School, Department of Dermatology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber/Brigham and Women’s Cancer Center, Center for Cutaneous Oncology, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896)
14 Dana-Farber Cancer Institute, Center for Neuro-Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Brigham and Women’s Hospital and Harvard Medical School, Department of Neurology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
15 Boston Children’s Hospital, Computational Health Informatics Program, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Danish Cancer Institute, Copenhagen, Denmark (GRID:grid.2515.3); Semmelweis University, Department of Bioinformatics and Department of Pathology, Forensic and Insurance Medicine, Budapest, Hungary (GRID:grid.11804.3c) (ISNI:0000 0001 0942 9821)
; Lakshminarayanan, Gitanjali 2 ; Diossy, Miklos 4 ; Qiu, Xintao 2
; El Zarif, Talal 2 ; Savignano, Hunter 2 ; Canniff, John 2 ; Madueke, Ikenna 2 ; Saliby, Renee Maria 2
; Zhang, Ziwei 1 ; Li, Rong 2
; Jiang, Yijia 2 ; Taing, Len 2 ; Awad, Mark 5 ; Chau, Cindy H. 6
; DeCaprio, James A. 7
; Figg, William D. 6
; Greten, Tim F. 8
; Hata, Aaron N. 9
; Hodi, F. Stephen 10 ; Hughes, Melissa E. 10 ; Ligon, Keith L. 11
; Lin, Nancy 10 ; Ng, Kimmie 10
; Oser, Matthew G. 10
; Meador, Catherine 9 ; Parsons, Heather A. 10
; Pomerantz, Mark M. 2 ; Rajan, Arun 12
; Ritz, Jerome 10
; Thakuria, Manisha 13 ; Tolaney, Sara M. 10
; Wen, Patrick Y. 14 ; Long, Henry 2
; Berchuck, Jacob E. 2
; Szallasi, Zoltan 15
; Choueiri, Toni K. 10
; Freedman, Matthew L. 1
1 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Eli and Edythe L. Broad Institute, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)
2 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Center for Functional Cancer Epigenetics, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
3 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Eli and Edythe L. Broad Institute, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)
4 Boston Children’s Hospital, Computational Health Informatics Program, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438)
5 Dana-Farber Cancer Institute, Harvard Medical School, Lowe Center for Thoracic Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
6 National Cancer Institute, National Institutes of Health, Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
7 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Brigham and Women’s Hospital, Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
8 National Cancer Institute, National Institutes of Health, Liver Cancer Program, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
9 Massachusetts General Hospital Cancer Center, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts General Hospital and Harvard Medical School, Department of Medicine, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
10 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
11 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Dana-Farber Cancer Institute, Department of Pathology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
12 National Cancer Institute, National Institute of Health, Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075)
13 Brigham and Women’s Hospital, Harvard Medical School, Department of Dermatology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Dana-Farber/Brigham and Women’s Cancer Center, Center for Cutaneous Oncology, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896)
14 Dana-Farber Cancer Institute, Center for Neuro-Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Brigham and Women’s Hospital and Harvard Medical School, Department of Neurology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
15 Boston Children’s Hospital, Computational Health Informatics Program, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Danish Cancer Institute, Copenhagen, Denmark (GRID:grid.2515.3); Semmelweis University, Department of Bioinformatics and Department of Pathology, Forensic and Insurance Medicine, Budapest, Hungary (GRID:grid.11804.3c) (ISNI:0000 0001 0942 9821)
Nature Medicine; New York
Volume
30
Issue
3
First page
907
End page
907
Publication year
2024
Publication date
Mar 2024
Place of publication
New York
Country of publication
United States
Publication subject
ISSN
10788956
e-ISSN
1546170X
Source type
Scholarly Journal
Language of publication
English
Document type
Corrections/Retraction
Publication history
Online publication date
2023-12-04
Milestone dates
2023-11-27 (Registration)
Publication history
First posting date
04 Dec 2023
ProQuest document ID
2972995391
Document URL
https://www.proquest.com/scholarly-journals/author-correction-liquid-biopsy-epigenomic/docview/2972995391/se-2?accountid=208611
Copyright
© The Author(s). 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2024-10-08
Database
ProQuest One Academic